Mikhail Blagosklonny’s Progressive Victory Finding Cancer Cure and Fighting Aging

Mikhail Blagosklonny is a distinguished research scientist with a strong focus on oncology. He serves as the senior editor of Oncotarget, a weekly journal that publishes peer-reviewed papers on topics such as oncology, neuroscience, pathology, pharmacology and many more medical fields.

He recently talked about the healing properties of Rapamycin, one of the most potent cancer drugs on the market. The drug is traditionally used to enable transplanted organs to achieve acceptance in the host body. It treats a rare lung condition and is also used as an anti-aging agent. Mikhail Blagosklonny previously served as a professor at Roswell Park Cancer Institute in New York. He has conducted extensive research in oncology and particularly the subject of aging.

He gives several reasons on why he advocates the use of Rapamycin. The drug has a comprehensive range of applications as well as advantages over classic versions. The immunosuppressive drug ensures organ transplants go smoothly.

Similarly, it is less toxic to the kidney than any other drug on the market. Rapamycin is an excellent option to treat major renal failure through a kidney transplant. In like manner, it is also the top prescription option for the treatment of rare lung disease. Other uses include the coating of coronary stents to suppress restenosis. Rapamycin boosts the immune system and stimulates its response to tumors.

This makes it a popular choice for cancer therapy. Additionally, it is useful in suppressing the growth of benign tumors in organs such as the brain and kidneys among others. It slows down the effects associated with aging and is prescribed in a cream format for the treatment of facial spots.

Mikhail Blagosklonny has been at the forefront of groundbreaking research into innovative treatment procedures that impact the quality of life. He graduated with a Ph.D. in experimental medicine from the First Pavlov State University. He then worked as an associate professor at New York Medical College. He has also served as a high-ranking researcher at Ordway Institute.

The scientist has a strong focus on cancer and anti-aging research. He is also a sought-after mentor and professor providing great inspiration and guidance to peers and students alike. He is excited to be at the forefront of discovering an effective, non-invasive and affordable cure for cancer. His research efforts have earned him widespread recognition among his peers.

The fame and prominence have only been accelerated by his role as the editor-in-chief of the Oncotarget journal. The journal recently upped its publish cycle to twice per week. As a result, it will accommodate the large volume of papers it receives and accelerate the dissemination of the information. He is also involved in editorial activities at numerous others journals including Aging, Cell Death & Differentiation as well as Cell Cycle among others.

One of his successful treatment procedures involves targeting the cancerous cells within the body while ensuring that the process does not affect healthy cells in the same areas. He is passionate about ensuring that research in cancer therapy and aging continues across the world.

Oncotarget Press Release:

*An in depth look at Oncotarget & their Press releases:

Oncotarget publishes research type materials which supply up to date information concerning various Cancers as well as any new research or treatment options. Oncotarget is published by Rapamycin Press. The material published by Oncotarget is informational, easy to read and always current. Oncotarget published an article in September which stated that there was a definite link between those diagnosed with Cancer and the strong possibility that they will experience financial hardship which may eventually lead to Bankruptcy. cancer is difficult to deal with by itself. exploring the possibility that a cancer diagnosis could Bankrupt you and your family is like receiving a double shot of very bad news.

Informational/ Immediate Release Articles:

Immediate release articles are continually published on Oncotarget’s web site. For example, an immediate release article which appeared on the web site the first week of October discussed advances in Cancer treatments. However, the article also discussed how the cost of Cancer treatment seems to steadily increase. Therefore, even though Cancer treatments are greatly improved which can very well prolong life; the down side is the cost of treatment can be astronomical even with adequate insurance coverage. Oncotarget also supplies useful information and statistics on various Cancers as well as the likelihood of occurrence according to age groups, racial groups, geographical area and likelihood of remission and re-occurrence. Therefore, these articles can be extremely helpful to researchers, Physicians, students, Registered Nurses and the public.Oncotarget divides its publications into two groups. First, recent news is discussed on the main page. Recent news normally consists of articles of public interest. In addition, the second group of articles on the Oncotarget web site includes any recent “Breakthrough’s and Discoveries. The Breakthrough’s and Discovery section would probably capture the interest of Professional Medical Personnel. However, anyone can read whatever article they find interesting or relevant to their current situation.

*Additional information/ web site resources:

Finally, Oncotarget is an excellent source when looking for accurate and current information on Cancer. In addition, each article or finding gives complete information on where the article originated and who originally published the material.Please view www.impactjournals.com for additional information about Oncotarget and the current topics available for review. Most articles published on the web site may be used for educational as well as instructional purposes. Therefore, the medical information published on the web site could be used for a teaching or information source in relation to undergraduate medical students.

Source of the article : https://oncotarget.msubmit.net/cgi-bin/main.plex

The Role Played by Clay Siegall in Cancer Research and Mitigation

Cancer is the one modern day sickness whose cure has eluded the medical community for many decades now. The best trials that have been done are radiotherapy and chemotherapy and this only works when cancer has not reached certain advanced stages. Scientists such as Clay Siegall have been researching on treatments that can deal with cancer once and for all and have confidence that their clinical trials are heading somewhere. Clay co-founded a clinical trials company known as Seattle Genetics in 1998. In the past twenty years, the company has been developing cures and treatment options for different types of tumors.

About two years ago, Siegall got his big break when the FDA approved one of the drugs he had been developing. The drug has since been adopted for use in treating different types of lymphomas in 66 countries. Also, Seattle Genetics is trading their shares on NASDAQ under the name SGEN. They have reported more than half a million dollars in drug sales since they started selling.

Clay states that things were not always as easy as they seem now. He confides that there were times when they were so strapped for cash that they couldn’t even afford a salary for their employees. The hard work and resilience have significantly paid off because now the company is selling their drugs abroad, and their chief marketer in Canada is Takeda Pharmaceuticals.

Clay states that the main aim of the research they are carrying out and the drugs they are creating is to build better outcomes by giving the patient strong antibody conjugates and directing them to the specific tumor cells. He adds that besides the one drug that has been approved, there are 11 others which are in different trial stages. He hopes that they will manage to get the drugs approved as well. To speed up the process of testing the drugs, they have expanded their capacity and hired more researchers to help with the process. Clay hopes that they will have an easy time dealing with FDA this time around and that their drugs will be a game changer in cancer treatment.

Eric Lefkofsky – Contributing in the Field of Cancer Research through his Tech Startup Tempus

Eric Lefkofsky is the founder of the world famous technology startup Groupon that went on to become a multi-billion dollar enterprise and is today worth at more than $2 Billion. It is an online platform that helps the customers to connect with the merchants offering attractive discounts and deals. Groupon has helped many businesses increase their turnover and reach out to their clients more efficiently. It helps companies with marketing their products and services at a much faster pace, and also helps with providing customers with promotional deals at a much more rapidly pace. It is a high-performance platform that is mutually beneficial for the customers as well as the companies.

Eric Lefkofsky has started many other companies, which includes Uptake Technologies, Lightbank Investments, Echo Global Logistics, and Tempus Inc. Tempus is a business that he started recently with the aim to integrate advanced technology in the field of cancer research. Eric Lefkofsky through life experiences came to the realization that the area of cancer research can develop and grow at a much faster pace if the data and information of various cases can be accumulated together.It is what Tempus does today. It gathers the clinical as well as patient outcome data from over 6,000 medical facilities and hospitals and makes it available to the physicians and research scholars so that the field of cancer research can progress smoothly by using the data active in their research. It helps the doctors to offer a highly personalized and focused treatment to the patients after understanding from the past cases, whether a particular treatment would be effective for them or not. Tempus also takes into account the genomic data, which helps in getting the accuracy needed in the cancer therapies.

Eric Lefkofsky is also the author of one of the most famous books named Accelerated Disruption. The book talks about how the new start-ups are making decades-old companies look like a newcomer overnight. Accelerated Disruption helps the companies to integrate the much-needed change to adapt to the modern business environment and use technology as a tool to innovate and advance in any given industry, and retaining the competitive advantage over the new start-ups.

 

Seattle Genetic Development of New Cancer Fighting Agents

Seattle Genetics, a company that conducts cancer research, has recently been the topic of many discussions due to their new development of cancer fighting agents. The company has been developing these new antibiotic treatments for the last several years and have recently been approved for funding that can take their research to a new level. Dr. Clay Siegall, the Chief Executive Officer and President of Seattle Genetics, has recently given an interview regarding the new changes at his company. He has stated that he is extremely excited about the changes that Seattle Genetics is making in the cancer research industry and hopes that this new advancement will be instrumental in the healing of millions of people who suffer from cancer.

The new development that Seattle Genetics has been working on for the last several years is comprised of a medication that actively fights cancer antibodies in a patients body.  These antibodies create cells that actually kill the healthy cells and grow at a swift rate so that white blood cells can not kill them. Now, there is a drug available that can specifically target the cancer cells and not the healthy cells in a patients body.

With most cancer fighting drugs, like chemotherapy for instance, the medicine works by targeting the cancer cells and the healthy cells in a patient’s body. The problem with these drugs have been that they generally cause the patient’s body to attack itself while it is attacking the cancer cells. This is the reason that most cancer patients become so ill and begin to lose their hair and the functionality in their bodies. The medicine has been formulated in such a way that it cannot distinguish between healthy and cancerous cells. This new development by Dr. Clay Siegall and his team at Seattle Genetics is a true innovation in the cancer research industry and can dramatically improve the lives of cancer patients around the world.

Read on…

http://executives.findthecompany.com/l/23957/Dr-Clay-B-Siegall-PhD

ADC Technology by Seattle Genetics

Cancer is one of those diseases which affect not only the patient but also their loved ones. When diagnosed with cancer, most patients see it as a death sentence from the beginning. The truth is that there are cures for different types of cancer. There are various treatment methods available and there are certain researchers and scientists who are still doing research to come up with even better and more effective treatment options.

When you have cancer, the doctors will start you on a treatment plan. Most of the time, the treatment involves the use of chemotherapy to kill the cancer cells. The treatment usually affects both the cancerous cells as well as the healthy ones. However, there is a company which has noticed this and has come up with a method of ensuring that only the cells with cancer are killed. The cells which are unaffected by cancer can be left alone to thrive.

Seattle Genetics is a company known in the biotechnology industry as a manufacturer and maker of innovative treatment technologies and products. They have come up with an innovative solution to this problem. This is in the form of a treatment known as ADC which actually means Anti-body Drug Conjugate. The technology sees to it that only cancerous cells are killed in the body.

The CEO and founder of Seattle Genetics is a reputed individual known as Clay Siegall. He founded the company in 1998 and he led it to where it is now. He is helped by a board of directors and he chairs the board. Mr Siegall is a scientist as well as an entrepreneur. He has gained recognition for his work both as a research with a passion and specialty in therapies, drugs and innovative treatment methods. As an entrepreneur, Siegall has been awarded several awards, including the 2012 Northwest Pacific Ernst & Young Entrepreneur of the Year.

Thanks to the ADC technology, patients can get the best treatment options for cancer and even recover faster after their sessions of chemotherapy. The team is driven by certain values among them integrity and a passion for whatever they do.

Read more:

http://www.ultragenyx.com/about/board/siegall/

http://www.pegsummit.com/uploadedFiles/PEGS/Agenda/15/PEGS-Interview-Siegall.pdf